446 related articles for article (PubMed ID: 31642059)
41. Advances in immunotherapy for triple-negative breast cancer.
Liu Y; Hu Y; Xue J; Li J; Yi J; Bu J; Zhang Z; Qiu P; Gu X
Mol Cancer; 2023 Sep; 22(1):145. PubMed ID: 37660039
[TBL] [Abstract][Full Text] [Related]
42. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
43. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
44. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract][Full Text] [Related]
45. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.
Liu H; Bai L; Huang L; Ning N; Li L; Li Y; Dong X; Du Q; Xia M; Chen Y; Zhao L; Li Y; Meng Q; Wang J; Duan Y; Ming J; Yuan AQ; Yang XP
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599021
[TBL] [Abstract][Full Text] [Related]
46. Triple-negative breast cancer-Role of immunology: A systemic review.
Oner G; Altintas S; Canturk Z; Tjalma W; Verhoeven Y; Van Berckelaer C; Berneman Z; Peeters M; Pauwels P; van Dam PA
Breast J; 2020 May; 26(5):995-999. PubMed ID: 31797488
[TBL] [Abstract][Full Text] [Related]
47. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
[TBL] [Abstract][Full Text] [Related]
48. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer.
Vito A; Rathmann S; Mercanti N; El-Sayes N; Mossman K; Valliant J
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063642
[TBL] [Abstract][Full Text] [Related]
49. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
50. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
51. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
52. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
53. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.
Shettigar A; Salunke R; Modi D; Mukherjee N
Int Immunopharmacol; 2023 Jun; 119():110250. PubMed ID: 37163922
[TBL] [Abstract][Full Text] [Related]
54. [Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer].
Zhao JL; Wang XJ; Cao X; Sun Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Jun; 43(3):475-480. PubMed ID: 34238426
[TBL] [Abstract][Full Text] [Related]
55. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer.
Huang Y; Zeng A; Song L
Front Immunol; 2023; 14():1255820. PubMed ID: 37691919
[TBL] [Abstract][Full Text] [Related]
56. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
57. [Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer].
Hao XP; Jiang ZF
Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):101-103. PubMed ID: 33378800
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in triple negative breast cancer: the immunotherapy era.
Marra A; Viale G; Curigliano G
BMC Med; 2019 May; 17(1):90. PubMed ID: 31068190
[TBL] [Abstract][Full Text] [Related]
59. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
[TBL] [Abstract][Full Text] [Related]
60. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.
Zheng Y; Li S; Tang H; Meng X; Zheng Q
Front Immunol; 2023; 14():1153990. PubMed ID: 37426654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
